Brief: Inflarx Announces Top-Line Shine Phase IIb Results For IFX-1 In Hidradenitis Suppurativa
05/06/2019 14:30
June 5 (Reuters) - Inflarx NV IF0G.F :
* INFLARX ANNOUNCES TOP-LINE SHINE PHASE IIB RESULTS FOR
IFX-1 IN
HIDRADENITIS SUPPURATIVA
* INFLARX-IFX-1 DID NOT DEMONSTRATE STATISTICAL SIGNIFICANT
DOSE
DEPENDENT EFFECT ON HIDRADENITIS SUPPURATIVA CLINICAL RESPONSE
RATE AT WEEK 16 AS PRIMARY ENDPOINT
* INFLARX- IFX-1 TREATMENT ACHIEVED A MAXIMUM HISCR RATE OF
51.5 %
AT WEEK 16, WHILE PLACEBO TREATMENT RESULTED IN A HISCR RATE OF
47.1 %
Source text: (https://bit.ly/2EQ7Yqz)
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum